Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) is an investigational autologous biologic therapy developed by researchers at the Universidad Nacional de Colombia for the treatment of severe dry eye syndrome, particularly in patients with Sjögren's syndrome. The treatment involves the subconjunctival injection of concentrated platelets, derived from the patient's own peripheral blood, into the area surrounding the lacrimal gland. These platelets release a variety of bioactive proteins, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and epidermal growth factor (EGF), which facilitate lacrimal gland regeneration and ocular surface epithelial repair. By modulating the inflammatory environment and promoting cellular restoration, PRP aims to improve tear production and alleviate the symptoms of chronic ocular surface disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma (Universidad Nacional de Colombia).